Diagnostics legislation
This article was originally published in The Gray Sheet
Executive Summary
A Medicare reform bill for in vitro diagnostic tests could be introduced in Congress by the end of the month. AdvaMed and other interested groups are close to finding a sponsor on the Hill for the legislation, which will focus on modernizing the current Clinical Laboratory Fee Schedule to make it more rewarding to innovative new tests, according to a rep from the medical device trade association. The bill will follow some of the recommendations included in a Lewin Group report on "The Value of Diagnostics," released in July 2005 (1"The Gray Sheet" Aug. 1, 2005, p. 9)...
You may also be interested in...
AdvaMed Cites Lewin Group Study In Call For Updated CMS Diagnostic System
AdvaMed is calling on Congress to revamp Medicare's diagnostic payment system following the release of a Lewin Group study concluding that the current Clinical Laboratory Fee Schedule (CLFS) is "archaic, impractical and severely flawed.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.